Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
तुलना करने के लिए मीट्रिक्स | VCYT | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधVCYTपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −368.4x | −3.9x | −0.7x | |
PEG अनुपात | −4.44 | −0.03 | 0.00 | |
क़ीमत/बुक | 2.9x | 3.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 8.0x | 31.5x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 0.8% | 203.0% | 46.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 11.1% | 6.9% | अनलॉक करें |